New Recommendations for Obesity Care
The World Health Organization has issued its first-ever guidelines on GLP-1 medications for adults with obesity, recommending long-term, continuous use when medically appropriate. The guidance covers semaglutide (Wegovy), liraglutide (Saxenda) and tirzepatide (Zepbound).
GLP-1s Aren’t a Standalone Solution
Published in JAMA, the guidelines stress that GLP-1 drugs must be paired with healthy eating, regular physical activity and ongoing counseling. WHO officials emphasize that obesity is a chronic disease requiring lifelong management, not a short-term fix.
Dr. Louis Arrone of Weill Cornell Medicine said the recommendations validate obesity treatment as mainstream medical care: “Treating obesity early — as a chronic disease — is finally moving into the mainstream.”
Access, Cost and Supply Remain Barriers
The WHO notes significant hurdles, including high drug prices, limited supply and unequal access globally. The organization urges countries to create fairer pathways to ensure those with the greatest medical needs receive treatment first.
How the Medications Help
GLP-1 drugs often reduce hunger and make it easier for patients to follow nutrition plans, according to Arrone. Many people feel full sooner and report less emotional pull toward certain foods. He also highlighted the importance of resistance training to prevent loss of muscle mass during rapid weight loss.
“Medicines work best when they go hand in hand with changes in eating habits and daily behaviors,” he said.
A Growing Global Crisis
More than 1 billion people currently live with obesity, a number projected to reach 2 billion by 2030. The WHO says future guidelines will focus on identifying and prioritizing those at highest risk.
A Call for System-Wide Change
The organization is urging member nations to “reboot” their approaches to obesity care by strengthening prevention, treatment and health-system capacity. Arrone described the shift as unprecedented: a move toward treating obesity proactively rather than waiting for complications to develop.
For more on this story, stay tuned to Que Onda Magazine.